# Surrozen, Inc.: financial statements, quarterly

SRZN · Nasdaq · CIK 1824893 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srzn.md) · [Financials](/companies/srzn/financials.md) · [Filings](/companies/srzn/filings.md) · [Insiders](/companies/srzn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srzn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-122318.md) | [0.0 d](/filings/0000950170-25-047712.md) | [0.0](/filings/0000950170-25-068046.md) | [0.0](/filings/0000950170-25-105847.md) | [10.0](/filings/0001193125-25-272422.md) | [0.7 d](/filings/0001193125-26-119818.md) | [1.0](/filings/0001193125-26-209179.md) | [1.0](/filings/0001193125-26-338120.md) | [1.0](/filings/0001193125-25-272422.md) | [0.5 d](/filings/0001193125-26-119818.md) | [5.0](/filings/0001193125-26-209179.md) | [5.0](/filings/0001193125-26-338120.md) |
| Research and development | $m | [6.1](/filings/0000950170-24-122318.md) | [6.1 d](/filings/0000950170-25-047712.md) | [5.2](/filings/0000950170-25-068046.md) | [5.3](/filings/0000950170-25-105847.md) | [5.2](/filings/0001193125-25-272422.md) | [5.4 d](/filings/0001193125-26-119818.md) | [6.6](/filings/0001193125-26-209179.md) | [6.0](/filings/0001193125-26-338120.md) | [7.8](/filings/0001193125-25-272422.md) | [9.0 d](/filings/0001193125-26-119818.md) | [9.3](/filings/0001193125-26-209179.md) | [8.5](/filings/0001193125-26-338120.md) |
| Operating income | $m | [(11.2)](/filings/0000950170-24-122318.md) | [(9.7) d](/filings/0000950170-25-047712.md) | [(9.1)](/filings/0000950170-25-068046.md) | [(9.0)](/filings/0000950170-25-105847.md) | [1.2](/filings/0001193125-25-272422.md) | [(8.6) d](/filings/0001193125-26-119818.md) | [(9.6)](/filings/0001193125-26-209179.md) | [(9.0)](/filings/0001193125-26-338120.md) | [(10.9)](/filings/0001193125-25-272422.md) | [(12.6) d](/filings/0001193125-26-119818.md) | [(10.5)](/filings/0001193125-26-209179.md) | [(10.4)](/filings/0001193125-26-338120.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-209179.md) | [0.0](/filings/0001193125-26-338120.md) | not reported | not reported | [0.0](/filings/0001193125-26-209179.md) | [0.0](/filings/0001193125-26-338120.md) |
| Net income | $m | [(10.4)](/filings/0000950170-24-122318.md) | [(8.9) d](/filings/0000950170-25-047712.md) | [(8.8)](/filings/0000950170-25-068046.md) | [(25.3)](/filings/0000950170-25-105847.md) | [(1.4)](/filings/0001193125-25-272422.md) | [(28.0) d](/filings/0001193125-26-119818.md) | [(27.0)](/filings/0001193125-26-209179.md) | [39.7](/filings/0001193125-26-338120.md) | [(71.6)](/filings/0001193125-25-272422.md) | [(183) d](/filings/0001193125-26-119818.md) | [(128)](/filings/0001193125-26-209179.md) | [50.2](/filings/0001193125-26-338120.md) |
| Diluted EPS | $ per share | [(5.14)](/filings/0000950170-24-122318.md) | not reported | [(4.24)](/filings/0000950170-25-068046.md) | [(7.99)](/filings/0000950170-25-105847.md) | [(0.44)](/filings/0001193125-25-272422.md) | not reported | [(7.43)](/filings/0001193125-26-209179.md) | [2.55](/filings/0001193125-26-338120.md) | [(8.36)](/filings/0001193125-25-272422.md) | not reported | [(11.65)](/filings/0001193125-26-209179.md) | [(0.41)](/filings/0001193125-26-338120.md) |
| Basic EPS | $ per share | [(5.14)](/filings/0000950170-24-122318.md) | not reported | [(4.24)](/filings/0000950170-25-068046.md) | [(7.99)](/filings/0000950170-25-105847.md) | [(0.44)](/filings/0001193125-25-272422.md) | not reported | [(7.43)](/filings/0001193125-26-209179.md) | [2.55](/filings/0001193125-26-338120.md) | [(8.36)](/filings/0001193125-25-272422.md) | not reported | [(11.65)](/filings/0001193125-26-209179.md) | [2.75](/filings/0001193125-26-338120.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [34.0](/filings/0000950170-24-122318.md) | [36.0](/filings/0000950170-25-047712.md) | [27.3](/filings/0000950170-25-068046.md) | [37.8](/filings/0000950170-25-105847.md) | [31.0](/filings/0001193125-25-272422.md) | [34.6](/filings/0001193125-26-119818.md) | [102](/filings/0001193125-26-209179.md) | [90.4](/filings/0001193125-26-338120.md) | [81.3](/filings/0001193125-25-272422.md) | [89.2](/filings/0001193125-26-338120.md) | [107](/filings/0001193125-26-209179.md) | [102](/filings/0001193125-26-338120.md) |
| Current assets | $m | [48.4](/filings/0000950170-23-061150.md) | [41.1](/filings/0000950170-25-047712.md) | [32.0](/filings/0000950170-24-055706.md) | [41.6](/filings/0000950170-24-095443.md) | [45.3](/filings/0000950170-24-122318.md) | [38.9](/filings/0001193125-26-119818.md) | [106](/filings/0000950170-25-068046.md) | [94.2](/filings/0000950170-25-105847.md) | [85.9](/filings/0001193125-25-272422.md) | [91.6](/filings/0001193125-26-338120.md) | [114](/filings/0001193125-26-209179.md) | [109](/filings/0001193125-26-338120.md) |
| Total assets | $m | [54.0](/filings/0000950170-23-061150.md) | [46.1](/filings/0000950170-25-047712.md) | [36.7](/filings/0000950170-24-055706.md) | [45.1](/filings/0000950170-24-095443.md) | [48.0](/filings/0000950170-24-122318.md) | [48.5](/filings/0001193125-26-119818.md) | [115](/filings/0000950170-25-068046.md) | [103](/filings/0000950170-25-105847.md) | [94.0](/filings/0001193125-25-272422.md) | [98.7](/filings/0001193125-26-338120.md) | [121](/filings/0001193125-26-209179.md) | [116](/filings/0001193125-26-338120.md) |
| Current liabilities | $m | [6.7](/filings/0000950170-23-061150.md) | [7.1](/filings/0000950170-25-047712.md) | [6.2](/filings/0000950170-24-055706.md) | [6.0](/filings/0000950170-24-095443.md) | [6.1](/filings/0000950170-24-122318.md) | [7.3](/filings/0001193125-26-119818.md) | [10.6](/filings/0000950170-25-068046.md) | [5.7](/filings/0000950170-25-105847.md) | [6.5](/filings/0001193125-25-272422.md) | [9.9](/filings/0001193125-26-338120.md) | [9.6](/filings/0001193125-26-209179.md) | [9.0](/filings/0001193125-26-338120.md) |
| Total liabilities | $m | [8.4](/filings/0000950170-23-061150.md) | [8.1](/filings/0000950170-25-047712.md) | [6.6](/filings/0000950170-24-055706.md) | [39.0](/filings/0000950170-24-095443.md) | [42.3](/filings/0000950170-24-122318.md) | [69.8](/filings/0001193125-26-119818.md) | [109](/filings/0000950170-25-068046.md) | [55.6](/filings/0000950170-25-105847.md) | [118](/filings/0001193125-25-272422.md) | [286](/filings/0001193125-26-338120.md) | [399](/filings/0001193125-26-209179.md) | [334](/filings/0001193125-26-338120.md) |
| Shareholders' equity | $m | [45.5](/filings/0000950170-24-122318.md) | [37.9](/filings/0001193125-26-119818.md) | [30.1](/filings/0001193125-25-272422.md) | [6.1](/filings/0001193125-25-272422.md) | [5.7](/filings/0001193125-25-272422.md) | [(21.4)](/filings/0001193125-26-338120.md) | [5.7](/filings/0001193125-26-338120.md) | [47.1](/filings/0001193125-26-338120.md) | [(23.5)](/filings/0001193125-25-272422.md) | [(188)](/filings/0001193125-26-338120.md) | [(278)](/filings/0001193125-26-338120.md) | [(219)](/filings/0001193125-26-338120.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.1) d](/filings/0000950170-24-122318.md) | [(7.3) d](/filings/0000950170-25-047712.md) | [(8.7)](/filings/0000950170-25-068046.md) | [(5.6) d](/filings/0000950170-25-105847.md) | [(6.8) d](/filings/0001193125-25-272422.md) | [3.5 d](/filings/0001193125-26-119818.md) | [(9.3)](/filings/0001193125-26-209179.md) | [(6.1) d](/filings/0001193125-26-338120.md) | [(9.0) d](/filings/0001193125-25-272422.md) | [(5.8) d](/filings/0001193125-26-119818.md) | [(12.5)](/filings/0001193125-26-209179.md) | [(7.4) d](/filings/0001193125-26-338120.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122318.md) | [0.0 d](/filings/0000950170-25-047712.md) | [0.0](/filings/0000950170-25-068046.md) | [0.0 d](/filings/0000950170-25-105847.md) | [0.0 d](/filings/0001193125-25-272422.md) | [0.0 d](/filings/0001193125-26-119818.md) | [0.0](/filings/0001193125-26-209179.md) | [0.0 d](/filings/0001193125-26-338120.md) | [0.0 d](/filings/0001193125-25-272422.md) | [0.1 d](/filings/0001193125-26-119818.md) | [0.1](/filings/0001193125-26-209179.md) | [0.0 d](/filings/0001193125-26-338120.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.0](/filings/0000950170-23-061150.md) | [0.0](/filings/0000950170-24-055706.md) | [2.0](/filings/0000950170-24-095443.md) | [2.0](/filings/0000950170-24-122318.md) | [0.0](/filings/0000950170-25-068046.md) | [0.0](/filings/0000950170-25-105847.md) | [0.0](/filings/0001193125-25-272422.md) | [0.0](/filings/0001193125-26-209179.md) | [8.5](/filings/0001193125-26-338120.md) | [0.0](/filings/0001193125-25-272422.md) | [0.0](/filings/0001193125-26-209179.md) | [23.1](/filings/0001193125-26-338120.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,753,558 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338120.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.